NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 3 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q3 2026, worth $15.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:15 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 23, 2026 | Mar 6, 2025 | Mar 21, 2024 | Mar 2, 2023 | Mar 3, 2022 |
| Operating expenses | $57.6M | $59.7M | $67.6M | $75.9M | $70.8M |
| Research and development | $44.9M | $41.5M | $47.9M | $54.2M | $50.2M |
| Selling, general and administrative | $12.7M | $15.7M | $19.7M | $21.7M | $20.6M |
| Operating income | -$57.6M | -$59.7M | -$67.6M | -$75.9M | -$70.8M |
| Income tax | $0 | – | – | – | – |
| Net income | -$55.8M | -$55.7M | -$62.7M | -$74.7M | -$69.4M |
| EPS, basic | $-19.65 | $-1.99 | $-2.25 | $-2.69 | $-2.51 |
| EPS, diluted | $-19.65 | $-1.99 | $-2.25 | $-2.69 | $-2.51 |
| Weighted shares, basic | 2.84M | 28.0M | 27.8M | 27.7M | 27.6M |
| Weighted shares, diluted | 2.84M | 28.0M | 27.8M | 27.7M | 27.6M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 23, 2026 | Mar 6, 2025 | Mar 21, 2024 | Mar 2, 2023 | Mar 3, 2022 |
| Cash and equivalents | $26.0M | $27.7M | $13.1M | $26.6M | $12.3M |
| Total current assets | $43.7M | $71.8M | $112.7M | $164.0M | $227.8M |
| Property, plant and equipment | $3.27M | $5.46M | $9.03M | $11.9M | $14.0M |
| Total assets | $50.2M | $80.9M | $128.0M | $184.2M | $242.4M |
| Accounts payable | $2.01M | $5.35M | $2.33M | $4.27M | $1.94M |
| Total current liabilities | $10.6M | $9.57M | $6.88M | $9.13M | $6.61M |
| Long-term debt | – | – | – | $0 | $0 |
| Total liabilities | $15.2M | $15.4M | $13.6M | $16.6M | $9.00M |
| Shareholders' equity | $34.9M | $65.5M | $114.4M | $167.5M | $233.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 23, 2026 | Mar 6, 2025 | Mar 21, 2024 | Mar 2, 2023 | Mar 3, 2022 |
| Operating cash flow | -$49.6M | -$40.8M | -$53.0M | -$53.9M | -$57.2M |
| Capital expenditures | – | $474.0K | $820.0K | $2.12M | $2.36M |
| Free cash flow | – | -$41.3M | -$53.8M | -$56.0M | -$59.6M |
| Depreciation and amortization | $2.20M | $2.90M | $3.70M | $4.10M | $4.30M |
| Stock-based compensation | $2.99M | $6.33M | $8.19M | $9.51M | $10.3M |
| Investing cash flow | $25.6M | $55.3M | $39.3M | $68.0M | $36.6M |
| Financing cash flow | $22.3M | $144.0K | $154.0K | $200.0K | -$3.27M |
| Net change in cash | -$1.75M | $14.6M | -$13.5M | $14.3M | -$23.9M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 9, 2026 | 4.58M | +70.9% | SEC |
| Jul 31, 2026 | 4.58M | +71.0% | SEC |
| May 1, 2026 | 3.61M | −87.1% | SEC |
| Feb 27, 2026 | 3.56M | −87.3% | SEC |
| Oct 31, 2025 | 2.68M | −90.4% | SEC |
| Aug 4, 2025 | 2.68M | −90.4% | SEC |
| Apr 28, 2025 | 28.1M | +0.3% | SEC |
| Mar 3, 2025 | 28.0M | +0.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-12 in Q3 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.